Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
DUTASTERIDE (UNII: O0J6XJN02I) (DUTASTERIDE - UNII:O0J6XJN02I)
Rising Pharmaceuticals, Inc.
DUTASTERIDE
DUTASTERIDE 0.5 mg
ORAL
PRESCRIPTION DRUG
DUTASTERIDE (dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: - improve symptoms, - reduce the risk of acute urinary retention (AUR), and - reduce the risk of the need for BPH-related surgery. DUTASTERIDE in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. DUTASTERIDE is not approved for the prevention of prostate cancer. DUTASTERIDE is contraindicated for use in: - Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, DUTASTERIDE may cause fetal harm when administered to a pregnant woman. If DUTASTERIDE is used during pregnancy or if the patient becomes pregnant while taking DUTASTERIDE, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.4), Use in Specific Population
DUTASTERIDE soft gelatin capsules 0.5 mg are oblong, opaque, dull yellow, gelatin capsules imprinted with “D05” with black edible ink on one side, packaged in bottles of 30 (NDC 64980-224-03) and 90 (NDC 64980-224-09) with child-resistant closures. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dutasteride is absorbed through the skin. DUTASTERIDE capsules should not be handled by women who are pregnant or who could become pregnant because of the potential for absorption of dutasteride and the subsequent potential risk to a developing male fetus [see Warnings and Precautions (5.4) ].
Abbreviated New Drug Application
DUTASTERIDE- DUTASTERIDE CAPSULE, LIQUID FILLED RISING PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE DUTASTERIDE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR DUTASTERIDE. DUTASTERIDE (DUTASTERIDE) SOFT GELATIN CAPSULES INITIAL U.S. APPROVAL: 2001 INDICATIONS AND USAGE DUTASTERIDE is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. DUTASTERIDE in combination with the alpha-adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: DUTASTERIDE is not approved for the prevention of prostate cancer. (1.3) DOSAGE AND ADMINISTRATION Monotherapy: 0.5 mg once daily. (2.1) Combination with tamsulosin: 0.5 mg once daily and tamsulosin 0.4 mg once daily. (2.2) Dosing considerations: Swallow whole. May take with or without food. (2) DOSAGE FORMS AND STRENGTHS 0.5-mg soft gelatin capsules (3) CONTRAINDICATIONS Pregnancy and women of childbearing potential. (4, 5.4, 8.1) Pediatric patients. (4) Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to DUTASTERIDE or other 5 alpha-reductase inhibitors. (4) WARNINGS AND PRECAUTIONS DUTASTERIDE reduces serum prostate-specific antigen (PSA) concentration by approximately 50%. However, any confirmed increase in PSA while on DUTASTERIDE may signal the presence of prostate cancer and should be evaluated, even if those values are still within the normal range for untreated men. (5.1) DUTASTERIDE may increase the risk of high-grade prostate cancer. (5.2, 6.1) Prior to initiating treatment with DUTASTERIDE, consideration should be given to other urological conditions that may cause similar symptoms. (5.3) Women who Izlasiet visu dokumentu